DIMERIX LIMITED — Capital/Financing Update 2008

Aug 31, 2008

==> picture [234 x 86] intentionally omitted <==

1 September 2008

Sun Biomedical Limited Cleansing statement

Sun Biomedical Limited (ASX:SBN) ( SBN ) seeks to rely on section 708A(5) of the Corporations Act 2001 (Cth) ( the Act ) and gives notice under section 708A(5)(e) of the Act of the following details:

• (a) On 25 August 2008, SBN issued:

  • (i) 64,474,786 fully paid ordinary shares ( Shares ) and 32,237,394 attaching options exercisable at $0.02 expiring 30 November 2010 ( Options ) under the shortfall under SBN’s prospectus dated 26 June 2008 for a total consideration of $644,748; and

  • (ii) 56,186,217 Shares to Dr Ming and Alice Sun as partial final consideration for the acquisition of Sun Biomedical Laboratories, Inc;

• (b) SBN issued the Shares and Options without disclosure to investors under Part 6D.2 of the Act;

• (c) as at the date of this notice, SBN has complied with:

  • (i) the provisions of Chapter 2M of the Act as they apply to SBN; and

  • (ii) section 674 of the Act; and

• (d) as at the date of this notice, there is no information to be disclosed that is “excluded information” within the meaning of section 708A(7) of the Act.

Yours sincerely

==> picture [102 x 60] intentionally omitted <==

Jim Hallam

Director

Sun Biomedical Investor Communications Limited Computershare T: +61 1300 850 505 | F: +61 3 9473 2500 | ABN 18 001 285 230 E: info@sunbiomed.com

ASX:SBN www.sunbiomed.com